ライフサイエンスコーパス: person-year

1 in patients with IM (0.38 to 17.08 per 1000 person years).

2 a result of ILD (crude rate, 2.7 per 10,000 person-years).

3 F or death in 1983 (incidence rate, 1.38/100 person-years).

4 sis (IR = 37.7/1000 person-years vs 4.4/1000 person-years).

5 ributable to ILD (crude rate, 6.4 per 10,000 person-years).

6 propriate shocks (incidence rate 2.2 per 100 person-years).

7 .6 to 5.8; excess absolute risk, 20.3/10,000 person-years).

8 6 per 100000 person-years to 1.51 per 100000 person-years).

9 ia progression (incidence rate, 155 per 1000 person-years).

10 , 305 cases of HF remained (0.88 per 100,000 person-years).

11 s of follow-up (incidence rate 3.3 per 1,000 person-years).

12 d schizophrenia during follow-up (49,582,279 person-years).

13 study period (total follow-up, 57.1 million person-years).

14 n cancer screening test (57.9 tests per 1000 person-years).

15 d highest in adults aged >65 years (1.7/1000 person-years).

16 e annual incidence rate, 7.4 events per 1000 person-years).

17 r-attributable mortality rate 327 per 100000 person-years).

18 mpared with the unexposed (rate = 7.21/1,000 person-years).

19 ed complications (incidence rate 1.4 per 100 person-years).

20 RS criteria (14.7 deaths [12.5-17.2] per 100 person-years).

21 ncidence rate, 8.2; 95% CI, 6.8-9.6 per 1000 person-years).

22 propriate shocks (incidence rate 0.9 per 100 person-years).

23 history of injection drug use (74.9 per 100 person-years).

24 US$126 for PrEP and US$406 for early ART per person-year.

25 no IR testing and increased costs by 200 USD/person/year.

26 h an overall incidence rate of 2.8 per 1,000 person-years.

27 als with HIV who were followed up for 24 031 person-years.

28 ears: 6.9 for SVR and 21.6 for NSVR per 1000 person-years.

29 no history of postpartum AD was 1.2 per 100 person-years.

30 ing a total of 17857 suicides during 4725445 person-years.

31 SCC, MM, and MCC were calculated per 100000 person-years.

32 l, mortality risk at 6 months was 61 per 100 person-years.

33 followed up in a tertiary center for 37 607 person-years.

34 503 seroconverted after follow-up of 22 891 person-years.

35 de mortality rate of 1,021 deaths per 10,000 person-years.

36 for an incidence rate of 34.6 cases per 100 person-years.

37 ation after first birth, it was 35.0 per 100 person-years.

38 rate was 42 (95% CI, 38.7-45.3) per 100,000 person-years.

39 this cohort, with an incidence of 11.4/1000 person-years.

40 g event was 21.5 (95% CI, 15.4-29.1) per 100 person-years.

41 incidence of 2.1 (95% CI 0.05-11.7) per 1000 person-years.

42 sttransplant skin cancer was 1437 per 100000 person-years.

43 ries was reduced from 28.9 to 24.3 per 1,000 person-years.

44 +/- 13 months of follow-up, totaling 10,322 person-years.

45 rall crude mortality was 9.8 deaths per 1000 person-years.

46 stimate of postdischarge suicides per 100000 person-years.

47 riable Poisson regression with an offset for person-years.

48 0 person-years and 3.3 hospitalizations/1000 person-years.

49 32 years of follow-up, encompassing 3643562 person-years.

50 (SHRs) and absolute excess risks per 10 000 person-years.

51 e interval [CI], 16.6-19.2) cases per 100000 person-years.

52 271 cases of incident vitiligo over 835,594 person-years.

53 tic events during the study was 1.22 per 100 person-years.

54 developed HCC with total follow-up of 1,363 person-years.

55 .1%), with an incidence rate of 121 per 1000 person-years.

56 these were followed longitudinally for 3939 person-years.

57 d pancreatic adenocarcinoma over 4.2 million person-years.

58 over a 12-year period, encompassing 949,330 person-years.

59 sion rate was 6.4 (95% CI: 1.3-18.7) per 100 person-years.

60 c event was 27.2 (95% CI, 20.3-35.7) per 100 person-years.

61 s per recipient; total follow-up time, 69590 person-years.

62 posed patients (incidence rate [IR] per 1000 person-years, 0.26; 95% CI, 0.23-0.29), 70 in patients e

63 rage for 10.9 years (a total of 19.6 million person-years), 11,517 cases of breast cancer occurred.

64 an average of 7.6 years (approximately 6396 person-years); 138 patients (16.4%) had no missing data

65 t to a cumulative incidence of 23.1 per 1000 person-years (14.0-36.2), and corresponding to 10.3% (5.

66 During 276526 person-years, 1834 of 49865 patients died (249 AIDS-rela

67 ) in the intervention group and 2.27 per 100 person-years (2.00-2.54) in the control group (adjusted

68 rn California Diabetes Registry (n = 434,806 person-years; 2007-2010).

69 sed children (hospitalization rates per 1000 person-years, 203.6 for exposed vs 219.3 for unexposed;

70 ausal at baseline in 1991; over 1.13 million person-years, 2041 women reported having natural menopau

71 Over a period of 1066572 person-years, 2046 KS cases were diagnosed.

72 ncidence fell from 5.2 to 4.1 cases per 1000 person-years (22% decline, 1-39).

73 n the baseline period to 16.2 cases per 1000 person-years (23% decline, 95% CI 7-36) in 2014-15.

74 factors.During a follow-up period of 15,947 person-years, 238 of 1226 (19.4%) women died of ASVD-rel

75 a decreased from 15.3 to 10.9 cases per 1000 person-years (29% decline, 12-42).

76 Over 11 years of follow-up (44152 person-years), 405 CHD and 228 stroke events occurred.

77 onia declined from 2.9 to 1.2 cases per 1000 person-years (58% decline, 22-77) in children aged 2-11

78 -up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 per

79 11 months and from 2.6 to 0.7 cases per 1000 person-years (75% decline, 47-88) in children aged 12-23

80 Estimated HIV incidence was 2.11 per 100 person-years (95% CI 1.84-2.39) in the intervention grou

81 mden and Islington and 51.3 patients per 100 person-years (95% CI 49.6-53.1) in South London and Maud

82 53.9 patients per 100 person-years (95% CI 52.1-55.8) in Camden and Islington

83 ing to a cumulative incidence of 71 per 1000 person-years (95% CI 56.5-89.3) and an incidence proport

84 hol-related mortality rate was 4.8 per 10000 person-years (95% CI, 4.1-5.6; n = 152) for the psoriasi

85 rge suicide rate was 484 suicides per 100000 person-years (95% CI, 422-555 suicides per 100000 person

86 (tuberculosis disease incidence 0.7 per 100 person-years [95% CI 0.4-1.1]), children with QFT conver

87 antly increased risk of disease (2.5 per 100 person-years [95% CI 0.4-9.4]; incidence rate ratio (IRR

88 ly increased disease incidence (28.0 per 100 person-years [95% CI 14.9-45.7]) compared with non-conve

89 the lowest mortality (225 deaths per 100 000 person-years [95% CI 145-304]), with low rates also show

90 mentary construction (701 deaths per 100 000 person-years [95% CI 593-809]), and housekeeping and fac

91 n-years of follow-up (incidence 0.93 per 100 person-years, 95% CI 0.80-1.08).

92 had died (all-cause mortality 118 per 10 000 person-years, 95% CI 115-121).

93 2, and June 30, 2016, (incidence 8.2 per 100 person-years, 95% CI 5.9-11.1), of whom 36 (86%) were di

94 azole users (n = 193; 15.3 cases per 100,000 person years; 95% confidence interval 13.3-17.7), with a

95 f TB disease (n = 86; 10.0 cases per 100,000 person years; 95% confidence interval 8.1-12.4) than ome

96 nt rate in the presence of CAC (2.8 per 1000 person-years; 95% CI, 1.5-5.4) relative to without CAC (

97 pisode psychosis (34.0 new cases per 100,000 person-years; 95% CI=31.5-36.6).

98 5-5.4) relative to without CAC (0.8 per 1000 person-years; 95%, CI 0.3-1.7) (P = .03).

99 neys followed for a median of 1.9 years (408 person-years), a greater proportion of recipients with D

100 s per 100 person-years to 0.66 cases per 100 person-years (adjusted incidence rate ratio, 0.58; 95% c

101 nd women, by 7% (from 358 to 332 per 100 000 person-years; adjusted incidence ratio 0.93, 95% CI 0.91

102 f autism spectrum disorder was 4.51 per 1000 person-years among children exposed to antidepressants v

103 Melanoma incidence per 100,000 person-years among lithium-exposed individuals was 67.4,

104 ed complications were 123.95 events per 1000 person-years among patients actively exposed to antithro

105 tithrombotic agents vs 80.17 events per 1000 person-years among patients not exposed to these drugs (

106 dysplasia (95% CI 1.5-7.2), and 7.3 per 100 person-years among patients with baseline high-grade dys

107 -years overall (95% CI 3.3-8.2); 3.3 per 100 person-years among patients with baseline low-grade dysp

108 onal grade (3.71 versus 1.96 events per 1000 person-years among those depressed versus nondepressed,

109 exposed to antidepressants vs 2.03 per 1000 person-years among unexposed children (between-group dif

110 nual incidence rates of MA-NGE were 4.9/1000 person-years and 0.7/1000 person-years for episodes invo

111 992 to 2014, corresponding to over 4 million person-years and 23,186 incident dementia cases.

112 ldren aged <5 years: 34.0 consultations/1000 person-years and 3.3 hospitalizations/1000 person-years.

113 m 1980 to 2014 covered more than 136 million person-years and compared people bereaved by spousal sui

114 Repeat self-harm per 1,000 person-years and suicide rates per 100,000 person-years

115 rate of anaphylaxis was 26 cases per 100 000 person-years and the one-year period prevalence was 0.04

116 es were higher among black men (6.9 per 1000 person-years) and black women (7.2 per 1000 person-years

117 0 person-years) than white men (4.4 per 1000 person-years) and white women (3.3 per 1000 person-years

118 h occurred in 1334 (incidence rate, 0.87/100 person-years), and HHF or death in 1983 (incidence rate,

119 in high-poverty neighborhoods (47.4 per 100 person-years), and people with a history of injection dr

120 During 26.6 million person-years at risk (mean follow-up 13.3 years [SD 6.4

121 The rate of AMD per 1000 person-years at risk was 5.2 (95% CI, 4.6-5.9) for patie

122 uring a mean follow-up of 20.5 years (374638 person-years at risk), 1639 survivors experienced 3115 s

123 Participants contributed 22,576 person-years at risk.

124 0 person-years and suicide rates per 100,000 person-years (based on cause of death information from t

125 es were observed among females (46.8 per 100 person-years), Black and Latino/Hispanic people (41.8 an

126 g ($24-$74 per test) and adherence ($400 per person-year), calibrated to achieve 72% suppression by 2

127 rbose group (436 [13%] of 3272; 3.17 per 100 person-years) compared with the placebo group (513 [16%]

128 noma-associated mortality (rate = 4.68/1,000 person-years) compared with the unexposed (rate = 7.21/1

129 core (29.4 deaths [95% CI 22.3-38.7] per 100 person-years) compared with those with an elevated SOFA

130 ve incidence of pregnancy was 106.0 per 1000 person-years, corresponding to 28.4% (22.8-35.0) of thes

131 2012; the annual incidence rates per 10 000 person-years declined among older individuals (rates in

132 ed complications were 191.61 events per 1000 person-years (difference, 117.3; 95% CI, 112.8-121.8) fo

133 ic hypoglycemia were 2200.9 episodes per 100 person-years' exposure (PYE) in the insulin degludec gro

134 470 928; incidence reduction of 4.4 per 1000 person-years) fewer decayed, missing, or filled teeth an

135 678; incidence reduction of 31.1 per 100 000 person-years) fewer incident cases of type 2 diabetes pe

136 of England were identified during 2 million person-years follow-up.

137 95% CI 2.9-9.1]; p < 0.001) and 2.3 episodes/person-year for AL compared to 0.5 for AL+PQ (rate ratio

138 incidence rate of P. vivax was 2.2 episodes/person-year for patients treated with CQ compared to 0.4

139 , older participants (7.5 vs 2.2 MI per 1000 person-years for adults 40 years and older vs < 40 years

140 es as the number of hospitalizations per 100 person-years for all causes, AIDS-defining illnesses, an

141 te outcome were 17.2, 12.5, and 11.4 per 100 person-years for Chagasic, other nonischemic, and ischem

142 -NGE were 4.9/1000 person-years and 0.7/1000 person-years for episodes involving primary care or hosp

143 s for participants with SCT and 4.0 per 1000 person-years for noncarriers.

144 not virally suppressed (6.3 vs 4.7 per 1000 person-years for participants with and without detectabl

145 The incidence rate for ESRD was 8.5 per 1000 person-years for participants with SCT and 4.0 per 1000

146 Incidence rates per million person-years for the 0-14 years and 0-19 years age group

147 rienced significantly lower risks, per 10000 person-years, for colorectal cancer (-6 cases [95% CI, -

148 ebo had significantly lower risks, per 10000 person-years, for diabetes (-19 cases [95% CI, -34 to -3

149 istically significantly increased, per 10000 person-years, for gallbladder disease (30 more cases [95

150 l contact after first birth was 55.4 per 100 person-years; for women with postpartum antidepressant m

151 dence rate of anaphylaxis was 42 per 100,000 person-years from 2001-2010 in Olmsted County, Minnesota

152 schemic stroke (0.80 vs. 0.94 events per 100 person-years; hazard ratio [HR], 0.92 [95% CI, 0.65 to 1

153 ifference, 2.48 [95% CI, 2.33-2.62] per 1000 person-years; hazard ratio [HR], 2.16 [95% CI, 1.64-2.86

154 ortality rates were 78 vs 80 deaths per 1000 person-years (HR, 0.93 [95% CI, 0.81-1.06]).

155 e donor vs male donor were 74 vs 62 per 1000 person-years (HR, 0.99 [95% CI, 0.87 to 1.13]); for a ne

156 onor, mortality rates were 74 vs 62 per 1000 person-years (HR, 1.01 [95% CI, 0.88-1.15]).

157 anial bleeding (0.39 vs. 0.77 events per 100 person-years; HR, 0.51 [CI, 0.33 to 0.79]) and more like

158 art failure (1.73 versus 3.01 events per 100 person-years; HR, 0.57; 95% CI, 0.50-0.65) and major adv

159 ular events (2.31 versus 3.45 events per 100 person-years; HR, 0.67; 95% CI, 0.60-0.75).

160 ial hemorrhage (2.12 vs. 2.63 events per 100 person-years; HR, 0.89 [CI, 0.72 to 1.09]) but were less

161 ial infarction (0.77 vs. 0.43 events per 100 person-years; HR, 1.88 [CI, 1.22 to 2.90]).

162 amputation (0.17 versus 0.09 events per 100 person-years; HR, 1.99; 95% CI, 1.12-3.51).

163 ) with the genetic duet; and deaths per 1000-person years in patients harboring neither mutation, BRA

164 th healthy microbiota (incidence 0.6 per 100 person years in PrEP group and 2.5 per 100 person-years

165 3.9%) during 1974-2013 (from 4.56 per 100000 person-years in 1974-1977 to 14.42 per 100000 person-yea

166 ar (95% CI, 0.6%-1.6%) (from 0.40 per 100000 person-years in 1994-1997 to 0.46 per 100000 person-year

167 ncidence rate increased from 10.9 per 100000 person-years in 2000 to 19.0 per 100000 person-years in

168 person-years in 1994-1997 to 0.46 per 100000 person-years in 2010-2013) overall and 2.9% per year (95

169 erson-years in 1974-1977 to 14.42 per 100000 person-years in 2010-2013), primarily related to increas

170 eased, from 2.72 in 2003 to 3.49 per 100,000 person-years in 2014, and this rise was higher among old

171 0000 person-years in 2000 to 19.0 per 100000 person-years in 2015 (P < .001 for trend).

172 of fatal and non-fatal self-harm per 100 000 person-years in adolescents aged 12-17 years in England.

173 The overall WSR was 140.6 per million person-years in children aged 0-14 years (based on 284 6

174 in non-HRV villages compared to 2.8 per 100 person-years in HRV villages, indicating an overall effe

175 incidence rate of ARD was 4.10 cases per 100 person-years in non-HRV villages compared to 2.8 per 100

176 incidence of HCC after SVR (1.82 vs 0.34/100 person-years in patients without cirrhosis; adjusted haz

177 ted rates of AD were 17.0 and 15.5 per 1,000 person-years in recipients and nonrecipients, respective

178 ly 0.1% of soldiers (1047.1 suicides/100 000 person-years in the 5 weeks after the visit).

179 33, 45, 52, and 58 was 0.5 cases per 10 000 person-years in the 9vHPV and 19.0 cases per 10 000 pers

180 ical pneumonia fell from 21.0 cases per 1000 person-years in the baseline period to 16.2 cases per 10

181 rson-years in the PrEP group and 3.5 per 100 person-years in the placebo group; efficacy 62.72% [95%

182 rson-years in the PrEP group and 3.5 per 100 person-years in the placebo group; efficacy 72.50% [95%

183 0 person years in PrEP group and 2.5 per 100 person-years in the placebo group; efficacy 76.55% [95%

184 new cases divided by the corresponding total person-years in the population.

185 rson-years in the urgent group vs 54 per 100 person-years in the post-stabilisation group; hazard rat

186 ediate microbiota (HIV incidence 1.8 per 100 person-years in the PrEP group and 3.5 per 100 person-ye

187 cterial vaginosis (HIV incidence 0.9 per 100 person-years in the PrEP group and 3.5 per 100 person-ye

188 years in the 9vHPV and 19.0 cases per 10 000 person-years in the qHPV groups, representing 97.4% effi

189 ity risk did not differ by group (70 per 100 person-years in the urgent group vs 54 per 100 person-ye

190 rates were 34.8, 37.3, 34.9, and 35.6 /1000 person-years in white women, white men, black men, and b

191 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396

192 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91;

193 e annual incidence of CDI and mrCDI per 1000 person-years increased by 42.7% (from 0.4408 to 0.6289 c

194 erse events than those without T2MI (per 100 person-years: MACE, 53.7 versus 21.1, P<0.001; all-cause

195 9203 individuals with depression, and 72441 person-years (mean follow-up, 3.7 years) were available.

196 cipants had a diagnosis of ILD during 75,232 person-years (median, 12.2 yr) of follow-up.

197 .2 [11.2] years) in the study, during 485322 person-years (median, 6.7 years) of observation, 5750 (8

198 During 24569 person-years, mild cognitive impairment was diagnosed in

199 ce of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence of VF at censoring

200 h an excess hospitalization rate per 100,000 person-years of 242.7 for IHD (P = 0.02), 271.8 for CHF

201 44 never deployed) were followed for 467,857 person-years of active-duty service time.

202 Our analysis included 3.36 million person-years of data, corresponding to an average of 310

203 ere diagnosed with HIV, contributing 448 839 person-years of follow up.

204 During 1,190,170 person-years of follow-up (1982-2012), there was no asso

205 During 873,376 person-years of follow-up (1990-2012), longer durations

206 patients, with an incidence of 11.5 per 100 person-years of follow-up (95% CI 11.4-11.7), during fir

207 58 397 participants died during 3 195 484 person-years of follow-up (average follow-up, 16.2 years

208 ontacts developed tuberculosis during 19 147 person-years of follow-up (incidence 0.93 per 100 person

209 Over 401 person-years of follow-up (mean, 3.6 years per patient;

210 During 895,916 person-years of follow-up evaluation through the Nationa

211 not differ between groups (293.3 per 100 000 person-years of follow-up in the intervention group vs 3

212 30 085 participants from 11 cohorts (278 955 person-years of follow-up), 1958 (6.5%) had subclinical

213 Over 10,327 person-years of follow-up, 252 participants developed di

214 HRs and 95% CIs of diabetes risk.In 494,741 person-years of follow-up, 5207 participants developed T

215 In >250 791 person-years of follow-up, 602 cancer cases were observe

216 cident cancers and 8956 deaths during 267145 person-years of follow-up, and 11.9% of decedents had a

217 of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.

218 10 414 deaths were registered over 1 058 538 person-years of follow-up, meaning the overall crude mor

219 During 4.51 million person-years of follow-up, mortality rates by occupation

220 During 847,934 person-years of follow-up, there were 1,851 incident inv

221 During more than 185,000 person-years of follow-up, there were 6834 cases of inci

222 Over 4,833,042 person-years of follow-up, we documented 8,631 incident

223 hich there were 17,085 deaths during 787,275 person-years of follow-up.

224 e hundred one participants contributed 178.7 person-years of follow-up.

225 luded in the analytical sample, with 429 986 person-years of follow-up.

226 We included >50000 persons with >250000 person-years of follow-up.

227 l of 27,215 participants contributed 202,034 person-years of follow-up: 74% male, median (IQR) age 42

228 her PRA phenotypes (incidence rates per 1000 person-years of follow-up: suppressed renin phenotype, 8

229 ncrease in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 f

230 participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident inf

231 urces were combined and used to provide 2134 person-years of observation on 1248 individuals.

232 incidence rate (AIR) of S Typhi per 100 000 person-years of observation ranged from 0 (95% CI 0-0) i

233 3 903 adults who jointly contribute 535 42 8 person-years of observation to the analyses and 9992 dea

234 Over the course of 18.5 million person-years of observation, 74 sudden cardiac arrests o

235 For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.

236 p participants and in 479 (15%; 3.41 per 100 person-years) of 3250 placebo group participants (hazard

237 e outcome occurred in 470 (14%; 3.33 per 100 person-years) of 3272 acarbose group participants and in

238 person-years) and white women (3.3 per 1000 person-years), older participants (7.5 vs 2.2 MI per 100

239 SOFA score (22.6 deaths [19.2-26.6] per 100 person-years) or those who met SIRS criteria (14.7 death

240 ent between those with (4.12 strokes per 100 person-years) or without (1.92 strokes per 100 person-ye

241 eptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1 extra breast cancer for

242 rate of dysplasia recurrence was 5.2 per 100 person-years overall (95% CI 3.3-8.2); 3.3 per 100 perso

243 1 per 100000 person-years to 99.7 per 100000 person-years (P < .001 for trend).

244 e mortality (19.00 vs. 42.89 events per 1000 person-years; p < 0.001) and the incidences of hemorrhag

245 .6-21.0] vs 12.9 [95% CI, 9.3-18.0] per 1000 person-years; P = .40) or peptic ulcers (10.9 [95% CI, 7

246 .7-15.5] vs 11.4 [95% CI, 8.0-16.2] per 1000 person-years; P = .86).

247 rhagic stroke (1.21 vs. 4.19 events per 1000 person-years; p = 0.006) were lower in the treated cohor

248 As per 100 person-years vs 0.60 TIAs per 100 person-years; p=0.0005) and all strokes or TIAs (7.85 vs

249 nd all strokes or TIAs (7.85 vs 2.36 per 100 person-years; p=0.001).

250 n-years (95% CI, 422-555 suicides per 100000 person-years; prediction interval, 89-2641), with high b

251 s-associated diarrhea incidence was 37.2/100 person-years (PY) (95% confidence interval [CI], 33.2-41

252 We followed participants for 35353 person-years (PY).

253 associated hospitalization rates per 100,000 person-years ranged from 9.5 to 12.2 for IHD, 7.7 to 9.1

254 acebo group (513 [16%] of 3250; 3.84 per 100 person-years; rate ratio 0.82, 95% CI 0.71-0.94, p=0.005

255 rson-years) or without (1.92 strokes per 100 person-years) reduced leaflet motion (p=0.10), subclinic

256 for those with IM (15.24 and 17.08 per 1000 person years, respectively).

257 ate of recurrent MI (41.1 vs. 30.1 per 1,000 person-years, respectively), a 43% higher rate of CHD ev

258 .49 to 1.57; 65.1 versus 46.4 tests per 1000 person-years, respectively), amounting to a 33% higher r

259 rate of CHD events (62.5 vs. 43.8 per 1,000 person-years, respectively), and a 15% lower rate of all

260 e placebo group (2.14 and 6.44 cases per 100 person-years, respectively), for a vaccine efficacy of 6

261 atino/Hispanic people (41.8 and 39.5 per 100 person-years, respectively), people living in high-pover

262 all-cause mortality (79.9 vs. 94.2 per 1,000 person-years, respectively).

263 , MM, and MCC were 812, 75, and 2 per 100000 person-years, respectively.

264 ed were 530.4-1548.3 and 57.3-378.7 per 1000 person-years, respectively.

265 000 (95% CI, .44-.95 [104 cases]) vaccinated person-years, respectively.

266 ted patients were 60.2 and 194.3 per 100,000 person-years, respectively.

267 cause mortality were 73.0 and 51.6 per 1,000 person-years, respectively.

268 1.5-5.5) and 7.8 (95% CI, 2.2-13.3) per 1000 person-years, respectively.

269 spitalization rates were 1.3 and 7.2 per 100 person-years, respectively.

270 of dementia (incidence, 7.4 v 4.4 per 1,000 person-years, respectively; adjusted hazard ratio, 1.02;

271 3.40 per 1000 person-years vs 2.05 per 1000 person-years, respectively; adjusted HR, 1.60 [95% CI, 0

272 onversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% conf

273 dised all-cause mortality rates (per 100 000 person-years), stratified by sex.

274 re found ranging from 13 to 12112 per 100000 person-years, strongly depending on factors like study p

275 person-years) and black women (7.2 per 1000 person-years) than white men (4.4 per 1000 person-years)

276 Despite their relatively low numbers of person-years, the highest age groups contributed most to

277 00 860 cases), the ASR was 185.3 per million person-years, the most common being lymphomas (ASR 41.8)

278 ts During accumulated follow-up of 1,469,518 person-years, there were 738 lung cancer diagnoses.

279 or HIV prevention) - from 1.17 cases per 100 person-years to 0.66 cases per 100 person-years (adjuste

280 fold from 2001 to 2014 (from 0.26 per 100000 person-years to 1.51 per 100000 person-years).

281 experienced an increase from 55.1 per 100000 person-years to 99.7 per 100000 person-years (P < .001 f

282 t ischaemic attacks (TIAs; 4.18 TIAs per 100 person-years vs 0.60 TIAs per 100 person-years; p=0.0005

283 f autism spectrum disorder was 3.40 per 1000 person-years vs 2.05 per 1000 person-years, respectively

284 r in persons with giardiasis (IR = 37.7/1000 person-years vs 4.4/1000 person-years).

285 Incidence per 100 person-years was 5.09 in birth cohorts before 1920, 3.11

286 elines, the 10-year ASCVD incidence per 1000 person-years was 8.1 (95% CI, 5.9-11.1) in the presence

287 appendicitis or appendectomy (in per 100,000 person-years) was 100 (95% CI: 91, 110) in Northern Amer

288 Over 2,187,425 person-years, we identified 3,549 incident breast cancer

289 During a follow-up of 366 073 person-years, we identified 4347 cases of incident type

290 Reference absolute rates per 1000 person-years were 1.12 (95% CI, 0.84-1.57) for subsequen

291 idence rates of sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.

292 with 95% confidence intervals (CI) per 1,000 person-years were as follows: non-biologic, 14.2 (11.5-1

293 Age-standardized incidence rates per 100,000 person-years were calculated by country and sex.

294 Incidence rates per 1000 person-years were calculated, and crude and adjusted haz

295 Risks, per 10000 person-years, were significantly increased for invasive

296 s with GA ranged from 0.53 to 15.24 per 1000 person years, whereas there was more variation in GC inc

297 When the analysis was restricted to person-years with exposure to PM2.5 of less than 12 mug

298 llowed on average for 8.3 years (3.9 million person-years) with a mean age of 21 years, 6,999 first s

299 27.2 (95% CI, 21.6-34.2) fractures per 1000 person-years, with an absolute rate difference of -17.6

300 h Poisson regression modelling as events per person-years x 100, and we assessed covariables as predi